BRCA1 and ovarian carcinoma: To evaluate the role of HR in responses to TMZ + ATRi, the BRCA1-null human ovarian cancer line UWB1.289 and its BRCA1-supplemented sub-line (UWB1.289-BRCA1) were examined.